**INTRODUCTION:** Breast implant associated anaplastic large cell lymphoma (BI-ALCL) is a rare type of non-Hodgkin lymphoma occurring in the fluid or capsule adjacent to breast implants. Screening of symptomatic patients requires demonstration of large lymphoid cells with uniform expression of CD30 protein on immunohistochemistry. This study investigates a novel, rapid, office-based, and economic in-situ enzyme-linked immunosorbent assay (ELISA) for screening BI-ALCL patients.

**METHODS:** A commercially available in-situ ELISA was standardized and validated for patients with confirmed BIA-ALCL diagnosis with clinical isolates and a laboratory strain. A panel of five pathologically confirmed BIA-ALCL patients were screened by serum, plasma, and peri-prosthetic effusion specimens and compared against serum, plasma, and non-neoplastic delayed seromas in six healthy control patients. Statistical analysis demonstrated assay consistency and reliability.

**RESULTS:** BIA-ALCL serum specimens and all control specimens were tested at full concentration, 1:100, 1:250, 1:500 and 1:1000 serial dilutions. All BIA-ALCL effusions demonstrated CD30 ELISA detection at full and all serial concentrations. BIA-ALCL plasma specimens were weakly positive at full concentration and no activity with serial dilution. BI-ALCL serum specimens and all control specimens were negative at all concentrations.

**CONCLUSION:** This is the first study to demonstrate a viable alternative to CD30 immunohistochemistry for the screening of BIA-ALCL. A CD30 ELISA represents a novel low-cost screening test, which may be used to screen suspicious aspirations of delayed periprosthetic fluid collections in an office-based setting. This preliminary study demonstrates reliability and efficacy, however prospective testing in an expanded cohort will be required to establish sensitivity and specificity.
